To evaluate the efficacy and safety of latanoprost compared with other glaucoma medications in the treatment of chronic angle-closure glaucoma (CACG) and to provide the basis for clinical medication.
Methods
Major literature databases were searched for randomized controlled trials (RCT) involving latanoprost among patients with CACG. Primary outcome measures were absolute changes in intraocular pressure (IOP) and incidence of ocular adverse events. Statistical analyses included the calculation of standardized mean difference (SMD) and relative risk (RR). The statistical analysis was performed using STATA version 12.0 software.
Results
Ten RCT involving 1096 patients were included in this meta-analysis. Analysis showed that latanoprost was not significantly different from other glaucoma medications in reducing IOP (SMD = 0.29, 95% confidence interval [CI] −0.02 to 0.59, p=0.069). Further subgroup analysis revealed that latanoprost was superior compared with timolol (SMD = 0.64, 95% CI 0.46 to 0.82, p<0.001) and marginally inferior to travoprost and bimatoprost (SMD = −0.19, 95% CI −0.35 to −0.02, p = 0.026). As for conjunctival hyperemia, latanoprost caused a higher proportion than timolol (RR = 2.36, 95% CI 1.27 to 4.37, p = 0.007). However, latanoprost was associated with lower incidence of conjunctival hyperemia (RR = 0.42, 95% CI 0.30 to 0.59, p<0.001), and with fewer occurrence of other ocular side effects (excluding conjunctival hyperemia) than travoprost and bimatoprost (RR = 0.61, 95% CI 0.48 to 0.78, p<0.001).
Conclusions
Travoprost and bimatoprost are superior in IOP control than latanoprost, but latanoprost is better tolerated in patients with CACG.
Get full access to this article
View all access options for this article.
References
1.
QuigleyHABromanATThe number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90:262–7.
2.
QuigleyHAGlaucoma. Lancet. 2011;377:1367–77.
3.
SawSMGazzardGFriedmanDSInterventions for angle-closure glaucoma: an evidence-based update. Ophthalmology. 2003;110:1869–78quiz 1878-91930.
4.
SharminiATYinNYLeeSSJacksonALStewartWCMean target intraocular pressure and progression rates in chronic angle-closure glaucoma. J Ocul Pharmacol Ther. 2009;25:71–5.
5.
ParrishRKPalmbergPSheuWPXLT Study Group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol. 2003;135:688–703.
6.
ZhaoJGeJSunXWangNIntraocular pressure-reducing effects of latanoprost versus timolol in Chinese patients with chronic angle-closure glaucoma. J Glaucoma. 2013;22:591–6.
7.
SihotaRSaxenaRAgarwalHCGulatiVCrossover comparison of timolol and latanoprost in chronic primary angle-closure glaucoma. Arch Ophthalmol. 2004;122:185–9.
8.
SakaiHShinjyoSNakamuraYNakamuraYIshikawaSSawaguchiSComparison of latanoprost monotherapy and combined therapy of 0.5% timolol and 1% dorzolamide in chronic primary angle-closure glaucoma (CACG) in Japanese patients. J Ocul Pharmacol Ther. 2005;21:483–9.
9.
ChenMJChenYCChouCKHsuWMComparison of the effects of latanoprost and bimatoprost on intraocular pressure in chronic angle-closure glaucoma. J Ocul Pharmacol Ther. 2007;23:559–66.
10.
WuLLHuangPGaoYXWangZXLiBA 12-week, double-masked, parallel-group study of the safety and efficacy of travoprost 0.004% compared with pilocarpine 1% in Chinese patients with primary angle-closure and primary angle-closure glaucoma. J Glaucoma. 2011;20:388–91.
11.
RojanapongpunPPandavSSReyesMREuswasAComparison of the efficacy and safety of bimatoprost and timolol for treatment of chronic angle closure glaucoma. Asian J Ophthalmol. 2007;9:239–44.
12.
KongXSunXGeLThe clinical study of latanoprost in treating with residual angle-closure glaucoma. Chin J Pract Ophthalmol. 2005;23:475–8.
13.
HowACSKumarRSChenYMA randomised crossover study comparing bimatoprost and latanoprost in subjects with primary angle closure glaucoma. Br J Ophthalmol. 2009;93:782–6.
14.
ChewPTKPongpunPREuswasALuD-WChuaJHuiS-PIntraocular pressure- lowering effect and safety of travoprost 0.004% and latanoprost 0.005% for the treatment of chronic angle closure glaucoma. Asian J Ophthalmol. 2006;8:13–9.
15.
ChewPTKAungTAquinoMVRojanapongpunPIntraocular pressure-reducing effects and safety of latanoprost versus timolol in patients with chronic angle-closure glaucoma. Ophthalmology. 2004;111:427–34.
16.
ChenM-JChenY-CChouC-KHsuW-MComparison of the effects of latanoprost and travoprost on intraocular pressure in chronic angle-closure glaucoma. J Ocul Pharmacol Ther. 2006;22:449–54.
17.
AungTWongHTYipCCLeongJYChanYHChewPTComparison of the intraocular pressure-lowering effect of latanoprost and timolol in patients with chronic angle closure glaucoma: a preliminary study. Ophthalmology. 2000107:1178–83.
18.
ChengJ-WCaiJ-PLiYWeiR-LA meta-analysis of topical prostaglandin analogs in the treatment of chronic angle-closure glaucoma. J Glaucoma. 2009;18:652–7.
19.
LouHZongYGeYRChengJWWeiRLEfficacy and tolerability of latanoprost compared with timolol in the treatment of patients with chronic angle-closure glaucoma. Curr Med Res Opin. 2014;3:1–7.
20.
LiTDickersinKCitation of previous meta-analyses on the same topic: a clue to perpetuation of incorrect methods?Ophthalmology. 2013;120:1113–9.
21.
MoherDCookDJEastwoodSOlkinIRennieDStroupDFImproving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analysesLancet. 1999;354:1896–900.
22.
JadadARMooreRACarrollDAssessing the quality of reports of randomized clinical trials: is blinding necessary?Control Clin Trials. 1996;17:1–12.
23.
SchulzKFChalmersIHayesRJAltmanDGEmpirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trialsJAMA. 1995;273:408–12.
24.
OrmeMCollinsSDakinHKellySLoftusJMixed treatment comparison and meta-regression of the efficacy and safety of prostaglandin analogues and comparators for primary open-angle glaucoma and ocular hypertension. Curr Med Res Opin. 2010;26:511–28.
25.
WebersCABeckersHJZeegersMPNuijtsRMHendrikseFSchoutenJSThe intraocular pressure-lowering effect of prostaglandin analogs combined with topical beta-blocker therapy: a systematic review and meta-analysis. Ophthalmology. 2010;117:2067–74.
26.
BeggCBMazumdarMOperating characteristics of a rank correlation test for publication bias. Biometrics. 199450:1088–101.
27.
EggerMDavey SmithGSchneiderMMinderCBias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.
28.
RosenthalRRubinDB[Selection models and the file drawer problem]: comment: assumptions and procedures in the file drawer problem. Stat Sci. 1988;3:120–5.
29.
RosenthalRMeta-analytic Procedures for Social Research: Applied Social Research Methods Series. Thousand OaksCASage Publications1991;6155.
30.
AungTChanYHChewPTKDegree of angle closure and the intraocular pressure-lowering effect of latanoprost in subjects with chronic angle-closure glaucoma. Ophthalmology. 2005;112:267–71.
31.
AungTLimMCCChanYHRojanapongpunPChewPTKConfiguration of the drainage angle, intraocular pressure, and optic disc cupping in subjects with chronic angle-closure glaucoma. Ophthalmology. 2005;112:28–32.
32.
AungTWongHTYipCCLeeDCBLeongJYNChewPTKA randomized double-masked study comparing latanoprost with timolol in patients with chronic angle-closure glaucoma. IOVS. 1999;40ARVO abstract 984.
33.
WaltersTRDuBinerHBCarpenterSPKhanBVanDenburghAM24-Hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial. Surv Ophthalmol. 2004; 49(Suppl 1): S26–35.
34.
SatoSHirookaKBabaTEfficacy and safety of switching from topical latanoprost to bimatoprost in patients with normal-tension glaucoma. J Ocul Pharmacol Ther. 2011;27:499–502.
35.
TorisCBCamrasCBYablonskiMEEffects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes. Ophthalmology. 1993;100:1297–304.
36.
SharifNAKellyCRCriderJYHuman trabecular meshwork cell responses induced by bimatoprost, travoprost, unoprostone, and other FP prostaglandin receptor agonist analogues. Invest Ophthalmol Vis Sci. 2003;44:715–21.
37.
KookMSChoHSYangSJKimSChungJEfficacy of latanoprost in patients with chronic angle-closure glaucoma and no visible ciliary-body face: A preliminary study. J Ocul Pharmacol Ther. 2005;21:75–84.
38.
SihotaRAgarwalHCProfile of the subtypes of angle closure glaucoma in a tertiary hospital in north India. Indian J Ophthalmol. 1998;46:25–9.
39.
DiggoryPCassels-BrownAVailAAvoiding unsuspected respiratory side-effects of topical timolol with cardioselective or sympathomimetic agents. Lancet. 1995;345: 1604–6
